NCT04465643View on ClinicalTrials.gov

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions
Nerve Sheath Tumors
Interventions
DRUG

Nivolumab

Nivolumab 4.5 mg/kg Q3W x 2

DRUG

Ipilimumab

Ipilimumab 1 mg/kg Q3W x 2

Trial Locations (1)

21287

Johns Hopkins Medical Institution, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Congressionally Directed Medical Research Programs

FED

collaborator

Cancer Research and Biostatistics Clinical Trials Consortium

NETWORK

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT04465643 - Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor | Biotech Hunter | Biotech Hunter